Mylan Gets New Emsam Patent Covering Delivery of Antidepressant Through Skin With Patch
PITTSBURGH - Drug maker Mylan Laboratories Inc. announced Wednesday that its Mylan Technologies unit received an additional patent covering the Emsam antidepressant patch.
Mylan said the patent, issued on July 4, covers the delivery of Emsam's active ingredient selegiline through the skin.
Somerset Pharmaceuticals Inc., which makes the patch for Mylan, has an exclusive license to the patent. Emsam is distributed by drug maker Bristol-Myers Squibb.
Shares of Mylan, which also reported better-than-expected first-quarter results on Wednesday, rose $2.13, or 10.5 percent, to $22.38 in midday trading on the New York Stock Exchange.
PITTSBURGH - Drug maker Mylan Laboratories Inc. announced Wednesday that its Mylan Technologies unit received an additional patent covering the Emsam antidepressant patch.
Mylan said the patent, issued on July 4, covers the delivery of Emsam's active ingredient selegiline through the skin.
Somerset Pharmaceuticals Inc., which makes the patch for Mylan, has an exclusive license to the patent. Emsam is distributed by drug maker Bristol-Myers Squibb.
Shares of Mylan, which also reported better-than-expected first-quarter results on Wednesday, rose $2.13, or 10.5 percent, to $22.38 in midday trading on the New York Stock Exchange.
posted by doublezero at
8:39 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home